Beyond Air Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Beyond Air (NASDAQ: XAIR) reported Q2 2026 revenue of $1.8 million and gross margin of 13%. It reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16-$18 million, including second-generation LungFit PH revenue pending FDA approval. The company is awaiting FDA review of a PMA supplement, expects a decision in 2H 2026, and raised up to $30.1 million.
How this was made
The 30-second read
Why it matters
The release combines (1) Q2 financial datapoints, (2) reaffirmed revenue guidance that explicitly includes second-generation LungFit PH only after regulatory approval, and (3) a financing package intended to fund international expansion and the US commercial launch pending FDA action.
Market read
Traders can frame the stock around FDA review timing, cash runway, and whether reaffirmed 2026/2027 revenue targets look credible given the cost structure and financing terms.
What to watch
Nasdaq minimum bid compliance and the fiscal year-end transition could affect near-term reporting cadence and investor interpretation of operating trends.
Background
Beyond Air is commercial-stage with its first LungFit PH system; the second-generation system requires FDA PMA supplement review.
Ticker impact
Beyond Air reported Q2 2026 revenue of $1.8M, reaffirmed 2026/2027 guidance, and said a PMA supplement is under FDA review for 2H 2026.
Likely volatility into the FDA decision window and around the conference call, with direction dependent on perceived launch probability and cash runway.
The article provides fresh, decision-relevant disclosures: quarterly financials, reaffirmed multi-year revenue guidance tied to regulatory approval, and a new financing up to $30.1M including $10.0M tied to FDA approval.
Market effects
Adds incremental signal for nitric-oxide medical device adoption and FDA PMA supplement execution risk in respiratory device/biopharma.
Limited direct regional spillover; primarily US regulatory and Nasdaq listing compliance optics.
International distribution expansion to 45+ countries is supportive, but remains contingent on regulatory approvals for the second-generation system.
Counterpoint
Reaffirmed guidance may already be priced in, and the key value driver remains FDA timing uncertainty rather than a new approval or definitive decision.
Key entities
- companyBeyond Air, Inc.
NASDAQ-listed nitric-oxide medical device and biopharmaceutical company reporting Q2 2026 results and FDA-related corporate update.
- regulatory milestoneLungFit PH second-generation PMA supplement
FDA review of the PMA supplement submitted in June 2025, with approval expected in 2H 2026 per the company.
- capital raiseUp to $30.1M financing
Upfront gross proceeds of $10.2M plus up to $20.0M from potential warrant exercises, including $10.0M tied to FDA approval.
